Fate Therapeutics Inc (FATE) Unusual Options Activity Today

Checking FATE unusual options activity helps you spot when traders are making outsized bets on Fate Therapeutics Inc before the broader market catches on. Fate Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor FATE unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching FATE unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking FATE unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and FATE unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.

The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Catalysts rarely arrive without a footprint, and FATE unusual options activity is often where that footprint shows up first. Our scanner tracks Fate Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at FATE unusual options volume on the call side or chasing put sweeps, Fate Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.